Genasense plus Rituxan Reported Active in Patients with Relapsed Non-Hodgkin's Lymphoma

Genta Inc. today announced the presentation of clinical data reporting the safety and activity of Genasense(R), the Company's lead anticancer drug, in combination with rituximab (Rituxan(R); Genentech IDEC). The trial was conducted in patients with relapsed and refractory non-Hodgkin's lymphoma (NHL) by investigators from the M.D. Anderson Cancer Center, Houston, TX, McMaster University, Hamilton, Ontario, and the Fox Chase Cancer Center, Philadelphia, PA. The data were presented by the trial's principal investigator, Dr. Barbara Pro, on Saturday at the International Conference on Malignant Lymphoma in Lugano, Switzerland.



In this study, Genasense was administered daily for 7 days on weeks 1, 3 and 5, and Rituxan was administered weekly for 6 weeks. Thirty-five patients who had failed a median of 2 prior chemotherapy regimens with or without rituximab were entered into this ongoing trial. To date, 6 patients have achieved a complete response, one of whom was refractory to prior rituximab therapy. Nine other patients have achieved a partial response for an overall response rate of 42%. Patients with the specific subset of follicular lymphoma showed a response rate of 56%. Twelve other patients have had stable disease. Side effects of the combination appeared qualitatively similar to that for rituximab alone, including but not limited to neutropenia, fever, infection, anemia and fatigue. Full Story

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap